SMAD2 and prostate carcinoma: These findings are consistent with results on the control of TGF-β signaling by a mutant p53 in human prostate carcinoma cell lines, showing that Smad2/3 activation is decreased upon overexpression of ShcA and enhanced when ShcA levels are reduced [60].